3/6
02:22 am
cprx
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
Low
Report
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio [Yahoo! Finance]
3/5
07:56 am
cprx
Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
Low
Report
Catalyst Pharmaceuticals (CPRX) was upgraded by Zacks Research from "hold" to "strong-buy".
3/3
01:06 pm
cprx
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Catalyst Pharmaceuticals (CPRX) had its price target raised by Citigroup Inc. from $33.00 to $35.00. They now have a "buy" rating on the stock.
3/1
04:40 am
cprx
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results [Yahoo! Finance]
2/28
08:32 pm
cprx
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]
Medium
Report
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns [Yahoo! Finance]
2/26
07:02 pm
cprx
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/26
04:04 pm
cprx
Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
04:36 pm
cprx
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance [Yahoo! Finance]
2/25
04:07 pm
cprx
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Medium
Report
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
2/24
08:33 am
cprx
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference [Yahoo! Finance]
2/24
08:03 am
cprx
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
Low
Report
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
2/19
11:49 am
cprx
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs [Seeking Alpha]
Low
Report
Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs [Seeking Alpha]
2/11
08:53 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
2/11
08:03 am
cprx
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Low
Report
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
2/7
04:17 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years [Yahoo! Finance]
1/19
05:21 pm
cprx
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory [Yahoo! Finance]
Medium
Report
Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory [Yahoo! Finance]
1/9
07:03 pm
cprx
Does Forbes' Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? [Yahoo! Finance]
Low
Report
Does Forbes' Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)? [Yahoo! Finance]
1/9
04:31 am
cprx
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? [Yahoo! Finance]
Low
Report
Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause? [Yahoo! Finance]
1/8
08:03 am
cprx
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
Low
Report
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
1/5
08:40 am
cprx
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) [Yahoo! Finance]
Low
Report
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) [Yahoo! Finance]
1/5
08:03 am
cprx
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
Low
Report
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
12/31
11:40 am
cprx
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? [Yahoo! Finance]
Low
Report
Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move? [Yahoo! Finance]
12/24
04:13 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
04:34 pm
cprx
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
11:42 am
cprx
Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 [Yahoo! Finance]
Low
Report
Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 [Yahoo! Finance]